CHO-H01

Phase 1Small molecule

CCho Pharma Inc.

CHO-H01 is one of 68 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Follicular LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Lymphoma

NCT05950165

Clinical

Trials by Indication[1]

Follicular Lymphoma1 trial

A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma

Unknown status·CCho Pharma Inc.·Phase 1·NCT03221348·24 enrolled

Lymphoma1 trial

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Recruiting·CCho Pharma Inc.·Phase 1/2·NCT05950165·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CHO-H01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHO-H01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHO-H01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cho Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCho Pharma Inc.

CHO-H01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Follicular Lymphoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News